Pharma Mar, S.A. (BME:PHM)
Spain · Delayed Price · Currency is EUR 84.50
-2.00 (-2.31%)
At close: Mar 18, 2026
Pharma Mar Cash Flow Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 74.99 | 26.13 | 1.14 | 49.36 | 92.86 |
Depreciation & Amortization | 8.02 | 5.72 | 4.72 | 4.89 | 4.56 |
Other Amortization | - | 1.05 | 1.03 | 1.01 | 1.03 |
Loss (Gain) From Sale of Assets | -0.75 | -0.84 | 1.93 | -0.01 | 0.03 |
Asset Writedown & Restructuring Costs | - | -0.28 | -1.75 | 1.48 | -0.18 |
Loss (Gain) From Sale of Investments | -0.33 | - | - | - | - |
Stock-Based Compensation | - | - | 0.3 | 0.39 | 0.34 |
Other Operating Activities | -19.89 | 6 | 14.09 | 9.42 | -11.55 |
Change in Accounts Receivable | -4.99 | -7.32 | 1.78 | 21.61 | -26.76 |
Change in Inventory | -2.13 | -12.68 | -11.54 | -17.21 | 1.4 |
Change in Accounts Payable | -12.76 | 11.23 | 3.39 | 1.79 | 7.19 |
Change in Unearned Revenue | 16.99 | -24.93 | -23.2 | - | - |
Change in Other Net Operating Assets | -6 | 1.95 | -5.34 | -34.41 | -43.23 |
Operating Cash Flow | 53.13 | 6.03 | -13.45 | 38.32 | 25.68 |
Operating Cash Flow Growth | 781.53% | - | - | 49.24% | -90.80% |
Capital Expenditures | -6.46 | -15.02 | -14.81 | -8.85 | -7.8 |
Sale of Property, Plant & Equipment | - | 0.89 | - | 0.01 | - |
Sale (Purchase) of Intangibles | -2.92 | -0.5 | -1.15 | - | - |
Investment in Securities | -56.31 | 15.66 | -27.09 | 19.72 | 26.28 |
Other Investing Activities | 4.9 | - | - | - | - |
Investing Cash Flow | -60.79 | 1.03 | -43.05 | 10.88 | 18.47 |
Long-Term Debt Issued | 1.33 | 15.41 | 7.2 | 1.54 | 5.83 |
Total Debt Issued | 1.33 | 15.41 | 7.2 | 1.54 | 5.83 |
Long-Term Debt Repaid | -5.66 | -9.56 | -8.36 | -10.2 | -15.27 |
Net Debt Issued (Repaid) | -4.33 | 5.86 | -1.15 | -8.66 | -9.44 |
Issuance of Common Stock | 15.87 | 18.91 | 18.61 | 57.23 | 33.55 |
Repurchase of Common Stock | -34.12 | -18.63 | -37.9 | -50.18 | -40.66 |
Common Dividends Paid | -13.95 | -11.42 | -11.69 | -11.76 | -10.87 |
Other Financing Activities | - | -0.07 | - | - | - |
Financing Cash Flow | -36.52 | -5.35 | -32.14 | -13.37 | -27.42 |
Foreign Exchange Rate Adjustments | -1.24 | 1.51 | -1.16 | 0.64 | 0.4 |
Net Cash Flow | -45.42 | 3.22 | -89.79 | 36.47 | 17.14 |
Free Cash Flow | 46.67 | -8.99 | -28.25 | 29.47 | 17.87 |
Free Cash Flow Growth | - | - | - | 64.87% | -93.52% |
Free Cash Flow Margin | 21.08% | -5.14% | -17.87% | 15.01% | 7.78% |
Free Cash Flow Per Share | 2.68 | -0.51 | -1.58 | 1.63 | 0.99 |
Cash Interest Paid | - | 2.47 | 2.42 | 2.38 | 3.37 |
Cash Income Tax Paid | - | -23.26 | -16.59 | -2.72 | 7.86 |
Levered Free Cash Flow | 20.35 | -20.15 | -12.59 | 33.11 | 4.75 |
Unlevered Free Cash Flow | 24.42 | -18.61 | -11.08 | 34.6 | 6.86 |
Change in Working Capital | -8.9 | -31.75 | -34.91 | -28.22 | -61.41 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.